{"id":"W2905172465","doi":"10.3747/co.25.4287","title":"Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Cegep de Saint Jerome; Regional Municipality of Durham; Royal Columbian Hospital; Dr. Georges-L.-Dumont University Hospital Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Cohort; Lung cancer; Internal medicine; Clinical trial; Randomized controlled trial; Cancer; Oncology; Demographics; Immunotherapy; Demography","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002652226,0.0001310566,0.0003954613,0.0003663651,0.00004140152,0.000003598176,0.0001214996,0.0001142889,0.001043161],"category_scores_gemma":[0.00001051011,0.0001241011,0.00008141688,0.0004267567,0.0001748528,0.00002391743,0.00002422242,0.0001916118,0.00001234401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001752296,"about_ca_system_score_gemma":0.002155473,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6115435,"about_ca_topic_score_gemma":0.952801,"domain_scores_codex":[0.9988199,0.00002802723,0.0003590441,0.0002527862,0.0001057237,0.0004345299],"domain_scores_gemma":[0.9992589,0.00003404187,0.0001219738,0.0002448583,0.0001415194,0.0001987134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006566696,0.000216085,0.9446967,0.0001517686,0.00007338521,0.00001668037,0.0006116042,7.811749e-7,0.002290347,0.00003089463,0.01072102,0.04053413],"study_design_scores_gemma":[0.003866275,0.0005525439,0.7655196,0.0002952072,0.0001136882,0.000006824021,0.00006114879,0.0004349088,0.00211806,0.00001069905,0.2268793,0.0001418127],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965625,0.002587077,0.000004309979,0.000664798,0.001669445,0.0006022661,0.00003193038,0.00001244826,0.0288027],"genre_scores_gemma":[0.9954714,0.00216336,0.00007468437,0.0002544072,0.0003906539,0.0001000385,0.00002652758,0.00001881362,0.001500079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3412576,"threshold_uncertainty_score":0.99987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04051589643830278,"score_gpt":0.3768204557669513,"score_spread":0.3363045593286486,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}